RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
RespireRx Pharmaceuticals Inc. (the “Company”) has prepared a platform summary and an executive summary with respect to each of its two development platforms, Ampakines and Cannabinoids. The Cannabinoid Platform Summary describes the Company”s Dronabinol program. The Ampakine Platform Summary describes the Company”s CX1739, CX717 and CX1942 programs. Each platform summary is a very short overview of the platform, including a brief background section and a brief discussion of recent developments. Each executive summary is a more extensive discussion of the respective platform, its related programs and potential applications, including substantially more detailed scientific information. In addition, the Company has prepared a short Financial Summary that summarizes certain recent market metrics and financial statement information, which financial statement information was drawn from the Company”s annual report on Form 10-K for the year ended December 31, 2016 and its quarterly report on Form 10-Q for the period ended March 31, 2017. Both platform summaries, both executive summaries and the Financial Summary are attached as exhibits to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.
RespireRx Pharmaceuticals Inc. ExhibitEX-99.1 2 ex99-1.htm Ampakines® RespireRx is developing a class of proprietary CNS-acting compounds known as ampakines,…To view the full exhibit click
About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)
RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea.